Core Viewpoint - The domestic gene sequencing market in China is experiencing significant changes, with BGI Group's subsidiary, BGI Genomics, leading advancements in high-throughput gene sequencing technology, particularly with the launch of the T7+ sequencer, which enhances capabilities and reduces operational costs [1][2][3]. Group 1: Product Development and Market Position - BGI Genomics launched the T7+ sequencer, an upgraded version of the T7, which integrates seven modules for improved throughput and speed while being environmentally friendly [2][3]. - The T7+ is recognized as the "world's strongest daily delivery capacity ultra-high-throughput gene sequencer," capable of producing up to 14Tb of data in 24 hours, setting a new industry record [3]. - The company has achieved a historical high in instrument sales for its long-read sequencing business, with over 700 units sold in the first half of 2025, marking a 60.35% year-on-year increase [3]. Group 2: Market Dynamics and Strategic Positioning - The Chinese Ministry of Commerce has placed Illumina on an unreliable entity list, banning its exports to China, which has created a favorable environment for domestic companies like BGI Genomics [2]. - BGI Genomics has a robust order backlog of approximately 900 million yuan, with 700 million yuan (78%) attributed to its long-read sequencing business, indicating strong future performance potential [4]. - The company is positioning 2025 as a pivotal year for its long-read strategy, following a series of product launches aimed at enhancing its market share and technological capabilities [2][4].